Status:
TERMINATED
Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients
Lead Sponsor:
Cook County Health
Conditions:
Microalbuminuria
Macroalbuminuric Diabetic Nephropathy
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Study Hypothesis: Reduction in albuminuria has been shown to decrease progression of diabetic nephropathy. In diabetic nephropathy patients treated with maximal antihypertensive doses with dual RAA...
Eligibility Criteria
Inclusion
- Macroalbuminuria \> 300mg/g
- Microalbuminuria 30-300mg/g
- Stable on max dose of an ACE-I or ARB (Can also be titrated to max dosage of ACE-I and ARB and stable on those doses for at least 2 weeks)
- Blood pressure \<130/80 mm Hg at time of enrollment
- Diabetic either Type 1 or 2
Exclusion
- GFR \<60 m/min
- Potassium \> 5mg/dl at time of enrollment
- Pregnant
- History of Angioedema
- ACE-I cough
- Allergic to ARB, ACE-I, DRI
- A1C \> 9%
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT00961207
Start Date
August 1 2009
End Date
September 1 2012
Last Update
October 28 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
John H Stroger Hospital of Cook County
Chicago, Illinois, United States, 60612